跳至主要内容
临床试验/NCT06867978
NCT06867978尚未招募1 期

A Prospective, Multi-Center, Assessor-Blinded Study on the Clinical Efficacy of CCeLL-In Vivo (Confocal Fluorescence Endomicroscopy) for Intraoperative Brain Tumor Diagnosis.

VPIX Medical0 个研究点目标入组 100 人开始时间: 2025年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
100
主要终点
Non-Inferiority of Diagnostic Accuracy (Percentage of Correct Normal/Tumor Classifications) of cCeLL Compared to Frozen Biopsy

研究概览

简要总结

The primary objective of this study is to demonstrate the non-inferiority of cCeLL compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, which is then read and analyzed by trained-professional for intraoperative diagnosis. The comparison will be held by the device with the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both methods will be compared in terms of their accuracy using the standard of practice, the final pathological diagnosis.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

盲法说明

Pathologists will perform diagnoses without access to patient medical records and will not see prior diagnostic results. They will assess tissue samples using only de-identified information, ensuring that fluorescence imaging results do not influence their evaluation. This approach eliminates bias and maintains the integrity of the study's diagnostic comparison.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female patients aged 18 years or older
  • Patients suspected of having a brain tumor who are scheduled for neurosurgery and are considered candidates for tumor resection
  • Patients who understand and have signed the informed consent form
  • The specimens used in this study must meet all of the following criteria:
  • Specimens obtained from patients who have agreed to participate in this clinical trial and who meet the inclusion criteria
  • Normal tissue specimens obtained unavoidably during tumor resection surgery in tumor patients

排除标准

  • Patients undergoing multiple surgeries
  • Patients with bacterial or viral infections
  • Patients who develop allergic reactions to the investigational medical device
  • Patients with a history of allergy to Indocyanine Green (ICG)
  • Patients with iodine hypersensitivity
  • Patients taking choleretic agents or rifampicin
  • Specimens meeting any of the following criteria will be excluded from this clinical trial:
  • Specimens with unclear tumor presence or carcinoma diagnosis results based on the reference standard permanent section analysis

研究组 & 干预措施

cCeLL - In vivo Imaging

Experimental

Participants diagnosed with brain tumors will receive an intravenous injection of Indocyanine Green (ICG) during surgery. The cCeLL - In vivo confocal laser fluorescence microscope will be used to capture real-time images of the tumor margins before tissue collection. Standard frozen section and permanent section analyses will then be performed for diagnostic comparison.

干预措施: cCeLL In vivo (Device)

cCeLL - In vivo Imaging

Experimental

Participants diagnosed with brain tumors will receive an intravenous injection of Indocyanine Green (ICG) during surgery. The cCeLL - In vivo confocal laser fluorescence microscope will be used to capture real-time images of the tumor margins before tissue collection. Standard frozen section and permanent section analyses will then be performed for diagnostic comparison.

干预措施: Indocyanine Green (Drug)

结局指标

主要结局

Non-Inferiority of Diagnostic Accuracy (Percentage of Correct Normal/Tumor Classifications) of cCeLL Compared to Frozen Biopsy

时间窗: Visit 1 (Surgery Day / Intervention Day) as D-Day

The diagnostic accuracy of cCeLL-In vivo will be assessed by measuring the percentage of correct normal/tumor classifications compared to the reference standard frozen biopsy. Non-inferiority will be determined using pre-specified statistical margins for sensitivity and specificity.

次要结局

  • Diagnostic Accuracy, Sensitivity, and Specificity of cCeLL Compared to Frozen Biopsy Across Tumor Types and Locations(Visit 1 (Surgery Day / Intervention Day) as D-Day)
  • Percentage of Non-Diagnostic Samples in cCeLL Imaging(Visit 1 (Surgery Day / Intervention Day) as D-Day)
  • Inter-Observer Agreement (Cohen's Kappa Score) Between Two Pathologists Using cCeLL-In vivo Images(Visit 1 (Surgery Day / Intervention Day) as D-Day)
  • Time (Minutes) Required to Obtain a Diagnosis Using cCeLL-In vivo vs. Frozen Biopsy Description:(Visit 1 (Surgery Day / Intervention Day) as D-Day)
  • Diagnostic Accuracy (Percentage of Correct Tumor Classifications) of AI-Based Brain Tumor Diagnosis Using cCeLL-In vivo Images(Visit 1 (Surgery Day / Intervention Day) as D-Day)

研究者

发起方
VPIX Medical
申办方类型
Industry
责任方
Sponsor

相似试验